Disease and treatment burden of patients with haemophilia entering the explorer6 non‐interventional study
European Journal of Haematology · 2024
DOI: 10.1111/ejh.14277 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Jerzy Windyga und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hemostasis Disorders and Internal Medicine, Laboratory of Hemostasis and Metabolic Diseases, Institute of Hematology and Transfusion Me…. Hauptthemen laut MEDLINE: Hemophilia A. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk (Denmark).
Abstract (Originalsprache)
Objectives
We aimed to characterise baseline disease and treatment burden in a large population with haemophilia A/B, both with (HAwI/HBwI) and without (HA/HB) inhibitors.
Methods
The prospective, non‐interventional explorer6 study included patients ≥12 years old with severe HA, severe/moderate HB or HAwI/HBwI of any severity, treated according to local standard of care (excluding previous/current exposure to concizumab or emicizumab). Baseline characteristics and historical clinical data were collected and patient‐reported outcomes, including treatment burden, were assessed.
Results
The explorer6 study enrolled 231 patients with haemophilia (84 HAwI/HBwI) from 33 countries. At baseline, patients with HA/HB treated with prophylaxis had the lowest median annualised bleeding rates (ABRs; 2.0), irrespective of haemophilia type; of these patients, 27.5% (HA) and 31.4% (HB) had target joints. Patients with HAwI/HBwI treated episodically reported the highest treatment burden. Of these patients, 28.5% (HAwI) and 25.1% (HBwI) performed sports activities in the month before screening.
Conclusion
Despite receiving routine clinical care, historical and baseline information from patients enrolled in explorer6 showed that patients with HA/HB treated episodically and patients with HAwI/HBwI had higher ABRs, higher treatment burden and participated in sports less than those with HA/HB treated with prophylaxis. Emerging treatments could be beneficial in addressing these unmet medical needs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hemostasis Disorders and Internal Medicine, Laboratory of Hemostasis and Metabolic Diseases, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
- Sahyadri Speciality Hospital, Pune, India.
- Pediatric Hematology-Oncology, Joe R. and Teresa Lozano Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
- Hiroshima University Hospital, Hiroshima, Japan.
- Yonsei University Severance Hospital, Seoul, Korea.
- Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico.
ORCID-Profile: Jerzy Windyga, Johnny Mahlangu
Förderung
- Novo Nordisk (Denmark)
Zitieren
APA
Windyga, J., Apte, S., Frei-Jones, M., Fujii, T., Lyu, C. J., Villarreal Martinez, L., Sathar, J., Stasyshyn, O., Tran, H., Zozulya, N., Brown Frandsen, R., Neergaard, J. S., Thaung Zaw, J. J., & Mahlangu, J. (2024). Disease and treatment burden of patients with haemophilia entering the explorer6 non‐interventional study. European Journal of Haematology. https://doi.org/10.1111/ejh.14277
Vancouver
Windyga J, Apte S, Frei-Jones M, Fujii T, Lyu CJ, Villarreal Martinez L, et al. Disease and treatment burden of patients with haemophilia entering the explorer6 non‐interventional study. European Journal of Haematology. 2024. doi:10.1111/ejh.14277
BibTeX
@article{Windyga2024,
author = {Windyga, Jerzy and Apte, Shashikant and Frei-Jones, Melissa and Fujii, Teruhisa and Lyu, Chuhl Joo and Villarreal Martinez, Laura and Sathar, Jameela and Stasyshyn, Oleksandra and Tran, Huyen and Zozulya, Nadezhda and Brown Frandsen, Renée and Neergaard, Jesper Skov and Thaung Zaw, Jay Jay and Mahlangu, Johnny},
title = {Disease and treatment burden of patients with haemophilia entering the explorer6 non‐interventional study},
journal = {European Journal of Haematology},
year = {2024},
doi = {10.1111/ejh.14277}
}
EUVIMED